Brio Capital Fund

Soligenix, Inc. is a late-stage biopharmaceutical company headquartered in Princeton, New Jersey, dedicated to developing and commercializing products aimed at treating rare diseases and addressing biodefense needs. The company operates through two primary segments: Specialized BioTherapeutics and Public Health Solutions. In the BioTherapeutics segment, Soligenix is advancing SGX301, a photodynamic therapy for cutaneous T-cell lymphoma, and SGX942, an innate defense regulator for oral mucositis in head and neck cancer, both in Phase 3 clinical trials. Additionally, it is developing a proprietary oral formulation of beclomethasone for severe gastrointestinal disorders, currently in Phase 1/2 trials. The Public Health Solutions segment focuses on developing a ricin toxin vaccine candidate, RiVax, which has completed early clinical trials, and SGX943, a therapeutic for antibiotic-resistant infections, currently in pre-clinical development. The company was previously known as DOR BioPharma, Inc. before rebranding to Soligenix in 2009.

The Square was launched in February in 1997 as the Internet's first community for students and alumni of select universities. The site was created as a grass roots group of people who wanted to interact among friends in a filtered, safe, private environment. The Square was the first Internet site to verify it's members and one of the first to include a strict privacy policy.